Prescription medication · LAMA / LABA Combination

glycopyrrolate/formoterol

Also sold as Bevespi Aerosphere. Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD).

Data updated 2026-05-15

5,311
FDA reports
1
InteractionFew interactions
Rx
Availability

What the data shows

glycopyrrolate/formoterol (Bevespi Aerosphere) is a prescription LAMA / LABA Combination, with 5,311 FDA adverse-event reports on file, with 1 documented drug interaction.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

glycopyrrolate/formoterol (Bevespi Aerosphere) is a prescription LAMA / LABA Combination. Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD).

Bevespi Aerosphere is a medicine that helps people with COPD breathe easier. It contains two medicines that work together to open airways.

Verify with FDA → · CMS NADAC pricing →

View Alternatives → Compare with Another Drug →

What it does

Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD).

Common side effects

Cough, Urinary tract infection

Key warnings

LABA medicines like formoterol, when used alone for asthma, increase the risk of serious asthma problems.

The sections below are summarized in plain English from glycopyrrolate/formoterol's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

This medicine combines two drugs: glycopyrrolate and formoterol. Glycopyrrolate is an anticholinergic that relaxes the muscles around your airways. Formoterol is a LABA that also relaxes airway muscles, helping you breathe better.

Side Effects (from patient reports)

Based on 5,311 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for glycopyrrolate/formoterol, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS)

Serious Warnings

LABA medicines like formoterol, when used alone for asthma, increase the risk of serious asthma problems. Bevespi Aerosphere is only for COPD, not asthma. Do not use Bevespi Aerosphere if you have asthma.

Known Drug Interactions

moderate formoterol

May potentiate effect of formoterol fumarate on cardiovascular system. ( 7.6 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol, a component of BEVESPI AEROSPHERE, may be potentiated [see Warnings and Precautions (5.3) ] . 7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of beta 2 adrenergic agonists such as formoterol, a component of BEVESPI AEROSPHERE.

Mechanism: Taking two drugs that work the same way can cause a stronger effect on your heart and nervous system. This happens because both drugs stimulate the same receptors in your body.

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

What should I do if Bevespi Aerosphere doesn't seem to be working?
Talk to your doctor right away. Do not increase your dose without talking to your doctor.
Can I use Bevespi Aerosphere for sudden breathing problems?
No, Bevespi Aerosphere is not a rescue inhaler. Use a rescue inhaler for sudden breathing problems.
Can I use Bevespi Aerosphere if I have asthma?
No, Bevespi Aerosphere is not for people with asthma.
How will I know when my inhaler is empty?
The inhaler has a dose counter that shows how many puffs are left. When the counter reaches zero, the inhaler is empty.
Can I use a spacer with Bevespi Aerosphere?
Bevespi Aerosphere has not been tested with spacers. Do not use a spacer unless your doctor tells you to.
What if I get Bevespi Aerosphere in my eyes?
Avoid spraying in eyes.
Can I take other medicines with Bevespi Aerosphere?
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How often should I clean my Bevespi Aerosphere inhaler?
The actuator should be cleaned weekly. Remove the canister and rinse the actuator with warm water for 30 seconds. Shake off excess water and allow to air dry completely before replacing the canister.
Is it okay to share my Bevespi Aerosphere inhaler with someone else?
No, never share your inhaler with anyone else, even if they have the same condition as you.
What should I do if I have trouble using the inhaler?
Talk to your doctor or pharmacist. They can show you the correct way to use the inhaler.
What are the common side effects of glycopyrrolate/formoterol?
The registry lists Cough, Urinary tract infection among the most-reported FAERS reaction terms for glycopyrrolate/formoterol. The compiled record contains 5,311 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does glycopyrrolate/formoterol interact with other medications?
The registry has 1 documented interaction rows for glycopyrrolate/formoterol. Notable source-record pairings include formoterol. These rows are not a complete medication review.
What drug class is glycopyrrolate/formoterol?
glycopyrrolate/formoterol belongs to the LAMA / LABA Combination drug class. It requires a prescription (Rx). Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD).
What pregnancy or breastfeeding source fields are listed for glycopyrrolate/formoterol?
The FDA label for glycopyrrolate/formoterol contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in LAMA / LABA Combination

Other drugs grouped near glycopyrrolate/formoterol - same-class peers and common alternatives.

aclidinium

Tudorza Pressair

Compare with glycopyrrolate/formoterol →

albuterol

Ventolin, ProAir

Albuterol is a drug that helps you breathe easier.

Compare with glycopyrrolate/formoterol →

albuterol/ipratropium

Combivent Respimat, DuoNeb

Combivent Respimat is a combination medicine that helps open your airways.

Compare with glycopyrrolate/formoterol →

beclomethasone

Qvar

Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.

Compare with glycopyrrolate/formoterol →

benralizumab

Fasenra

Fasenra is a medicine that can help treat severe asthma and EGPA.

Compare with glycopyrrolate/formoterol →

Compare glycopyrrolate/formoterol vs aclidinium side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on glycopyrrolate/formoterol

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for glycopyrrolate/formoterol

The FDA label for glycopyrrolate/formoterol (sold under brand names such as Bevespi Aerosphere) classifies it as a prescription-only medication in the LAMA / LABA Combination class. Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD). Official labeling lists 2 commonly reported side effects, including Cough, Urinary tract infection.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 5,311 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated moderate severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: March 24, 2023

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page